{"name":"Altimmune, Inc.","slug":"altimmune-inc","ticker":"","exchange":"","domain":"","description":"Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on developing next-generation immunotherapies and vaccines. The company's pipeline includes several candidates in various stages of development, targeting infectious diseases and metabolic disorders.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":41000,"revenueGrowth":105,"grossMargin":0,"rdSpend":66432000,"netIncome":-88093000,"cash":43760000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Pandemic Influenza Vaccine","genericName":"Pandemic Influenza Vaccine","slug":"pandemic-influenza-vaccine","indication":"Pandemic influenza prevention","status":"phase_3"}]}],"pipeline":[{"name":"Pandemic Influenza Vaccine","genericName":"Pandemic Influenza Vaccine","slug":"pandemic-influenza-vaccine","phase":"phase_3","mechanism":"A live attenuated intranasal vaccine that stimulates mucosal and systemic immune responses against pandemic influenza strains.","indications":["Pandemic influenza prevention"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxQa1lhS3oxVnR6WllVNWs3SmRMYTZ5T3hNSTFoQmFELXAxZGFUeWttak53SkhDZTBKaHJzclNnWWtMZDZZREpCbDZRazRqVWpOZEN0RUxtUGFMNHhGblRTODVtd0d4Q3YxaUctbUhTUjAwdjRmQzNvX0tNTkVSQnNyQVVJaEpvWHltWmJXN1lHT25xZjJSSGRId3Q1a1FlMTh1dFF0QXZKdE4?oc=5","date":"2026-03-06","type":"pipeline","source":"Seeking Alpha","summary":"Altimmune Reports FY25 Financials: Why Is Big Pharma Staying Away (NASDAQ:ALT) - Seeking Alpha","headline":"Altimmune Reports FY25 Financials: Why Is Big Pharma Staying Away (NASDAQ:ALT)","sentiment":"neutral"},{"date":"2026-03-06","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-05","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxOVUlJam1Id3ZHZWRMajZybXJZVUdFUUxVMU1pMmVrRlNLelgxZ2JMN0laQWhHdUxkNUVzNlc1bXhVTjVYdUcxcnRBZFotSnMwZ1JGNjg4amlvTHVrMW9uQnNKTVFzT2J2eWJYX3FsUFVHdXNxcGpVYXUxSGh1bm1WYmVIanQtQjM0anRkYmh5UkdWUUVua19tX2VQLTluZWtaNEtBcE13?oc=5","date":"2026-02-03","type":"trial","source":"Seeking Alpha","summary":"Altimmune Outlook: Where Pemvidutide Phase 3 Is Heading In 2026 (NASDAQ:ALT) - Seeking Alpha","headline":"Altimmune Outlook: Where Pemvidutide Phase 3 Is Heading In 2026 (NASDAQ:ALT)","sentiment":"neutral"},{"date":"2026-02-03","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxPUjMwYjRIR2NOV1AxOEp2T3BCX3R1eC1MdVlpd1RSd3VhLXBRVFJuekZNYi1nVkVPR0o1a1dKR1RXY0lvNWo1bjNfVUZyRzJNck5mSV9kTjNqS0NTRW44dlFYeDM5aTFPWkhIU2tQcjFIcjdZSWJPeWFDLWR1QmdlYXduaGZWX1dJcjY1Y0dya2c0N3hxYXg1cG83eWpnV1FY?oc=5","date":"2026-01-06","type":"regulatory","source":"Finviz","summary":"ALT Stock Up 17% After Pemvidutide Gets FDA Breakthrough Tag for MASH - Finviz","headline":"ALT Stock Up 17% After Pemvidutide Gets FDA Breakthrough Tag for MASH","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxOd3pELWxBcUYtcUlabWlEamo5RkFlSlBfVTNWTlZzQUpNOGxYSUtxTjVqaHFSWHJLZ3dMNENWME1LN1NMTEtoY194NHJUVEE5SlJSTGJaWm5nRkhyU1pNR3BnOTVMV2dJQlE2Sld2WklVZlFMZXVqVFlqa2N3NXpyT1ZKSDZKY1AwVDF6Sg?oc=5","date":"2025-12-09","type":"pipeline","source":"Morningstar Australia","summary":"2 companies poised to capitalize on the rise of GLP-1 drugs - Morningstar Australia","headline":"2 companies poised to capitalize on the rise of GLP-1 drugs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxPLWlvRTJHSmJOWjQzZWtBWGlVSUgxVW5POW9ueVNfWWhSWUxWcWdiaEVJNWJZWUFmVDM1ZTJ5cjZLVXQyalQ4QmVUdUsxSXpsR0VmNVc1UkxoVlZCdXpZMjBpd3lZcFQxN2YtMHBOTk1ZclpUcjFZTTNScGVXN2JsZUtYU3ExQ08yaUhWVjh4RDdiZVYydkxXbHc2a0d5dEJhU1dr?oc=5","date":"2025-12-03","type":"pipeline","source":"BioCentury","summary":"Former Intercept CEO Durso succeeding Garg as Altimmune CEO - BioCentury","headline":"Former Intercept CEO Durso succeeding Garg as Altimmune CEO","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0wFBVV95cUxQY1dvTllPRzQ3dDhUcm1wTEhjLVJadUpaYzJ4S3B4Z0JPdldVcFFsWVJJc2NBZWMwTUxlS1hfSTJQdEoxSnZfci0xRXBVZlkyakMtQXNQdU1Zbzg4THlyLVVwMzhtX3NIRzNrbm5SWDcxYjQ1TXY5RVVxcEQzckhHbHJoX1lSZWxjRW9FdTVOa0Q2WXRVbTlfLTVaYk90ZEl5b2NXbXdRODlFQ0pKUkc4Y1UwOFRKWkktbkhIaW1DRDFXcDhEVXYtV0t6cVJDN1haSkxz?oc=5","date":"2025-12-01","type":"pipeline","source":"BioBuzz","summary":"People on the Move: Altimmune Names Jerry Durso as Incoming CEO as Vipin Garg, Ph.D., Prepares Transition - BioBuzz","headline":"People on the Move: Altimmune Names Jerry Durso as Incoming CEO as Vipin Garg, Ph.D., Prepares Transition","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxQSHRDbDBCYkN4NXVHRWVGTEYwR2ZQSW1GLUJPTjRvUnpQWFNaVVBTaHJkdTN0SU1vTmdWbmNTREwxb1lFck16VWIxeWZlX2xyZkVUN3hEV0JNNFBncmU1dEFOU0MwU2lJR2EtZDluZUZISzF0dlhWMFVjZkEyclhvU01GbUJzbHJCdGw1YTd2WVVFMEF2bDlZazNUR2ZTTlNYZ0JKallZUWstcG53bWJjY2lVdjVleHFHZjdj?oc=5","date":"2025-12-01","type":"pipeline","source":"Quiver Quantitative","summary":"Altimmune, Inc. Announces CEO Transition as Jerry Durso Succeeds Vipin Garg, Ph.D. - Quiver Quantitative","headline":"Altimmune, Inc. Announces CEO Transition as Jerry Durso Succeeds Vipin Garg, Ph.D.","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxNdjZGOVdITnBxX3IyLXNUa1EzeVhCU0lOem1kSTUzaHNDTXBiT1dpWWhzNU5yM2pMX19PSTdzYWhiaUxRdHdkRElRY01LN3N2ODBlRGcxVlViYzdsUjI5TjhBMjl1a05TdjFtcUFDVUhsMWdJODI4ZkdDS2o4cjdScHdpS01pcGZyMjEtVDRLQ0FSQmVzb3pfSktwc0RzSXFSS2xHd1RiT05yWEJBeGc?oc=5","date":"2025-12-01","type":"pipeline","source":"The Business Journals","summary":"Gaithersburg drug developer Altimmune names new CEO as current chief readies exit - The Business Journals","headline":"Gaithersburg drug developer Altimmune names new CEO as current chief readies exit","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxQREJ0QlNiRDFCQlltZU80OEZNaEtULXVOdmROYjBFS1pNenhtSHN2aU9jT0dkdnJDM1ljVm1RdzZFU0RYdXpDR2FEbXA3QUdIaVFCSEwwak1TaEk4WlB5TVpSek1lVDZaaFFSZU03a293U1ZFdGlqX3JsMkFPVFpHSE9rNkFja0xpMEtvYWlleXk2UDdVYVctZFU5R1g2ZW9TQmVkZU5fTE03M1lzWmtQb3FjMA?oc=5","date":"2025-10-30","type":"regulatory","source":"Seeking Alpha","summary":"Altimmune: Competitor Buyouts Plus Regulatory And Clinical Progress (NASDAQ:ALT) - Seeking Alpha","headline":"Altimmune: Competitor Buyouts Plus Regulatory And Clinical Progress (NASDAQ:ALT)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxPR0JtQUt1aWtDNUphTVNyVE44Y2hOZ1hVd3IwWHVzbUJ2VXlyR3FUMEhTa0JFMzhHeE92dnQxanliV2xCVUE2UndETzdXdTlldm5ZNVJQSlhaeU5jbXlKSG84a29pTFZGbEdOdmpQYUVId0l2TzZTcHZKV0p6M1hjZjZUOHZXaHhKLWJNamtGWDV5Tkd0TnZma2RjNmNmd0haZWdmSkJLQ0VySkNfVnBRc1dQY0I?oc=5","date":"2025-09-15","type":"pipeline","source":"Stock Titan","summary":"30-Year Pharma Veteran Linda Richardson Joins Altimmune as CCO to Lead Pemvidutide Commercialization - Stock Titan","headline":"30-Year Pharma Veteran Linda Richardson Joins Altimmune as CCO to Lead Pemvidutide Commercialization","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2AFBVV95cUxPMkVzV1FsSXktbGxaTTNzSTJnX3pzcExfZ3F0YlRaLWhyM21iZW44TVVPaGJZNGZ6aTlYSGVGaFV3VjNtdk5sZ3lHNUpMNlpGVGZjQndUOEZzYjZ0WlVaTHpoSDU4RE0xa3JEemhrRXoxdkNMMjNfeU5aU0Q3enpVMXNVSDRDb3VsUjZtRENSN3lTVU1PdmJNWE9teHFCVnh6UW1GeWtIYk9vUXRBWTNPTXNVZU9qdTZlY05JTG9ESl9PdnpMTENZSW9YQ0pELVBVakRqMGtGOGs?oc=5","date":"2025-06-26","type":"trial","source":"Reuters","summary":"Altimmune shares slump as weight-loss drug's fatty liver trial data disappoints - Reuters","headline":"Altimmune shares slump as weight-loss drug's fatty liver trial data disappoints","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMic0FVX3lxTE1EVTU5UUM0TWs0c01URU1sa29VZmhhY19vVDhFX1pjOE1yZVozcHFTTnhJM19PWTVZVWprQzhTejF1Wmc5NlkzQ1huYnhENkhsOGJDcEZaVy1LLUh2WDhxcWEwUGw2NWg4bEE0XzZ5bVBzdUU?oc=5","date":"2025-03-14","type":"pipeline","source":"StocksToTrade","summary":"Altimmune: Unlocking the Pharma Puzzle​ - StocksToTrade","headline":"Altimmune: Unlocking the Pharma Puzzle​","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar","revenue":41000,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":41000,"period":"2025-12-31"},{"value":20000,"period":"2024-12-31"},{"value":426000,"period":"2023-12-31"},{"value":-68000,"period":"2022-12-31"},{"value":4410000,"period":"2021-12-31"},{"value":24266274,"period":"2011-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":66432000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-88093000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":43760000,"cashHistory":[],"totalAssets":279929000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":null}